Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTDVAKP)

• DTT Name: HUMAN interleukin-6 receptor (IL6R)
• Synonyms: Membrane glycoprotein; Interleukin-6 receptor; IL-6R; IL-6 receptor
• Gene Name: IL6R
• BioChemical Class: Cytokine receptor
• UniProt ID: IL6RA_HUMAN ; IL6RB_HUMAN
• TTD ID: T86513
• Sequence:
  MLAVGCALLAALLAAPGAALAPRRCPAQEVARGVLTSLPGDSVTLTCPGVEPEDNATVHW
  VLRKPAAGSHPSRWAGMGRRLLLRSVQLHDSGNYSCYRAGRPAGTVHLLVDVPPEEPQLS
  CFRKSPLSNVVCEWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQYSQESQKFSCQLAV
  PEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPANITVTAVARNPRWLSVTWQD
  PHSWNSSFYRLRFELRYRAERSKTFTTWMVKDLQHHCVIHDAWSGLRHVVQLRAQEEFGQ
  GEWSEWSPEAMGTPWTESRSPPAENEVSTPMQALTTNKDDDNILFRDSANATSLPVQDSS
  SVPLPTFLVAGGSLAFGTLLCIAIVLRFKKTWKLRALKEGKTSMHPPYSLGQLVPERPRP
  TPVLVPLISPPVSPSSLGSDNTSSHNRPDARDPRSPYDISNTDYFFPR
• Function: Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
• KEGG Pathway:
  EGFR tyrosine kinase inhibitor resistance (hsa01521)
  Cytokine-cytokine receptor interaction (hsa04060)
  Viral protein interaction with cytokine and cytokine receptor (hsa04061)
  HIF-1 signaling pathway (hsa04066)
  PI3K-Akt signaling pathway (hsa04151)
  JAK-STAT signaling pathway (hsa04630)
  Hematopoietic cell lineage (hsa04640)
  Th17 cell differentiation (hsa04659)
  Non-alcoholic fatty liver disease (hsa04932)
  Human cytomegalovirus infection (hsa05163)
  Coronavirus disease - COVID-19 (hsa05171)
  Pathways in cancer (hsa05200)
• Reactome Pathway:
  MAPK3 (ERK1) activation (R-HSA-110056)
  MAPK1 (ERK2) activation (R-HSA-112411)
  Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807)
  Transcriptional regulation of granulopoiesis (R-HSA-9616222)
  Potential therapeutics for SARS (R-HSA-9679191)
  Interleukin-6 signaling (R-HSA-1059683)

Molecular Interaction Atlas (MIA) of This DTT

2 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[2]
Tocilizumab	DM7J6OR	Giant cell arteritis	4A44.2	Approved	[1]

References

• [1] Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0.
• [2] IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57.